NCT04427254

Study of the Sars-Cov2 Neuroinvasiveness - COVID19

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Fondation Ophtalmologique Adolphe de Rothschild · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.

Conditions

• COVID19

Interventions

Type	Name	Description
DRUG	Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies	Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies

Timeline

• Start date: 2020-06-26
• Primary completion: 2022-11-25
• Completion: 2022-11-25
• First posted: 2020-06-11
• Last updated: 2023-07-11

Locations

1 site across 1 country: France